Conclusion Based on the current evidence , BTX-A may be an effective and safe option for the treatment of neuralgia .
Aim This meta- analysis was performed to evaluate the efficacy and safety of botulinum toxin-A ( BTX-A ) for the treatment of neuralgia .
Electrophysiologically identified piriformis syndrome is successfully treated with incobotulinum toxin a and physical therapy
INTRODUCTION Piriformis syndrome is entrapment of the sciatic nerve by the piriformis muscle . METHODS In this article we describe a 56-person r and omized , double-blind , controlled study involving physical therapy and incobotulinum toxin A or placebo .  Inclusion criteria were 3-SD delay of posterior tibial ( PT ) or fibular ( FN ) H-reflexes on flexion , adduction , and internal rotation ( FAIR ) testing , and normal paraspinal electromyographic findings . Outcome measures included adverse side effects , visual analog scale ( VAS ) findings , and H-reflex delay on the FAIR test . RESULTS Mean intervention VAS score decreased significantly more compared with placebo at 2 , 4 , 6 , 8 , 10 , and 12 weeks post-injection ( P < 0.0001 ) . FAIR test scores for PT , but not FN , decreased significantly more compared with placebo at 2 , 4 , 6 , and 8 weeks post-injection ( PT : P = 0.038 , 0.003 , 0.003 , and 0.046 ) . Adverse effects were minimal . VAS slope and PT FAIR test results varied significantly ( P < 0.0001 ) . CONCLUSION Incobotulinum toxin A chemodenervation may be useful for treating piriformis syndrome as identified by the FAIR test . Muscle Nerve 56 : 258 - 263 , 2017
Conclusion Based on the current evidence , BTX-A may be an effective and safe option for the treatment of neuralgia .
Aim This meta- analysis was performed to evaluate the efficacy and safety of botulinum toxin-A ( BTX-A ) for the treatment of neuralgia .